PMID- 17004103 OWN - NLM STAT- MEDLINE DCOM- 20070301 LR - 20181201 IS - 0167-594X (Print) IS - 0167-594X (Linking) VI - 81 IP - 2 DP - 2007 Jan TI - Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. PG - 139-48 AB - In this study, we investigated the mRNA and protein expression of nine tumour antigens in human glioblastoma multiforme with a view to their possible use in dendritic cell-based immunotherapy. Expression of ALK, EGFRvIII, GALT3, gp100, IL-13Ralpha2, MAGE-A3, NA17-A, TRP-2 and tyrosinase were studied by real-time RT-PCR on frozen tissues using a series of 47 tumour samples from patients with glioblastoma. Results were compared with non-neoplastic brain expression or glioblastoma samples with very low levels of expression near the limits of detection for EGFRvIII and MAGE-A3, as these latter two antigens were not detected in non-neoplastic brain. Tumour antigens showing a 5-fold increase in mRNA expression were considered as positive, and only antigens displaying an mRNA over-expression in a significant number of cases were analysed by immunohistochemistry on paraffin-embedded sections. Using real time RT-PCR, we found EGFRvIII, gp100, IL-13Ralpha2 and TRP-2 to be positive in 64, 38, 32 and 21% of cases, respectively. While we observed no over-expression for ALK, GALT3 and tyrosinase, 3 samples out of 47 were positive for MAGE-3 and 1 sample for NA17-A. More than 25% of tumour cells showed strong protein expression in 13, 34, 85 and 96% of GBM samples for gp100, TRP-2, EGFRvIII and IL-13Ralpha2, respectively. Interestingly, protein expression of at least 3 antigens was observed in 38% of cases. These results point out the importance of EGFRvIII, IL-13Ralpha2 and, to a less extent gp100 and TRP-2, for developing an immunotherapy strategy against glioblastoma. FAU - Saikali, Stephan AU - Saikali S AD - Departement d'Anatomie et cytologie pathologiques, Hopital Pontchaillou, Rennes, France. FAU - Avril, Tony AU - Avril T FAU - Collet, Brigitte AU - Collet B FAU - Hamlat, Abderrahmane AU - Hamlat A FAU - Bansard, Jean-Yves AU - Bansard JY FAU - Drenou, Bernard AU - Drenou B FAU - Guegan, Yvon AU - Guegan Y FAU - Quillien, Veronique AU - Quillien V LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20060927 PL - United States TA - J Neurooncol JT - Journal of neuro-oncology JID - 8309335 RN - 0 (Antigens, Neoplasm) RN - 0 (Biomarkers, Tumor) RN - 0 (Interleukin-13 Receptor alpha2 Subunit) RN - 0 (Membrane Glycoproteins) RN - 0 (Membrane Proteins) RN - 0 (PMEL protein, human) RN - 0 (RNA, Messenger) RN - 0 (Trp2 protein, vertebrate) RN - 0 (epidermal growth factor receptor VIII) RN - 0 (gp100 Melanoma Antigen) RN - EC 2.7.10.1 (ErbB Receptors) SB - IM MH - Adult MH - Aged MH - Antigens, Neoplasm/genetics/*metabolism MH - Biomarkers, Tumor/genetics/metabolism MH - Brain Neoplasms/genetics/*metabolism/pathology MH - ErbB Receptors/genetics/*metabolism MH - Female MH - Glioblastoma/genetics/*metabolism/pathology MH - Humans MH - Immunotherapy MH - Interleukin-13 Receptor alpha2 Subunit/genetics/*metabolism MH - Male MH - Membrane Glycoproteins/genetics/*metabolism MH - Membrane Proteins/genetics/*metabolism MH - Middle Aged MH - Prognosis MH - RNA, Messenger/metabolism MH - Reverse Transcriptase Polymerase Chain Reaction MH - Survival Rate MH - gp100 Melanoma Antigen EDAT- 2006/09/28 09:00 MHDA- 2007/03/03 09:00 CRDT- 2006/09/28 09:00 PHST- 2006/04/24 00:00 [received] PHST- 2006/07/12 00:00 [accepted] PHST- 2006/09/28 09:00 [pubmed] PHST- 2007/03/03 09:00 [medline] PHST- 2006/09/28 09:00 [entrez] AID - 10.1007/s11060-006-9220-3 [doi] PST - ppublish SO - J Neurooncol. 2007 Jan;81(2):139-48. doi: 10.1007/s11060-006-9220-3. Epub 2006 Sep 27.